Product Information

Registration Status: Active

DBL CISPLATIN INJECTION 1mg/ML is approved to be sold in Singapore with effective from 1988-04-05. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN00762P.

This product contains Cisplatin 1mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.

This product is manufactured by HOSPIRA AUSTRALIA PTY LTD in AUSTRALIA.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.


For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Mechanism of Action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.


Following cisplatin doses of 20 to 120 mg/m^2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, testicle, pancreas, and spleen; and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration.
Volume of distribution at steady state = 11-12 L/m^2


* 15-16 L/h/m^2 [total body clearance, 7-hour infusion of 100 mg/m^2] * 62 mL/min/m^2 [renal clearance, 2-hour infusion of 100 mg/m^2] * 50 mL/min/m^2 [renal clearance, 6- to 7-hour infusion of 100 mg/m^2] The renal clearance of free (ultrafilterable) platinum also exceeds the glomerular filtration rate indicating that cisplatin or other platinum-containing molecules are actively secreted by the kidneys. The renal clearance of free platinum is nonlinear and variable and is dependent on dose, urine flow rate, and individual variability in the extent of active secretion and possible tubular reabsorption.

Active Ingredient/Synonyms

CDDP | Cis-DDP | cis-diamminedichloroplatinum(II) | Cisplatin |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank